|
1
|
André MPE, Federico M, Fortpied C, Girinsky T, Meignan M, Raemaekers J. Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al. J Clin Oncol 2017; 35:2853-2854. [PMID: 28682682 DOI: 10.1200/jco.2017.74.0068] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Marc P E André
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Massimo Federico
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Catherine Fortpied
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Théodore Girinsky
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Michel Meignan
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - John Raemaekers
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|